MedPath

Study on Recurrent Breast Cancer and Repeated Radiation Therapy

Not Applicable
Not yet recruiting
Conditions
Recurrent Breast Carcinoma
Registration Number
NCT06704659
Lead Sponsor
Turku University Hospital
Brief Summary

This study explores whether recurrent breast cancer can be safely treated with breast-conserving surgery and repeated radiation therapy in cases where patients have previously undergone radiation. Traditionally, recurrent breast cancer has been treated by removing the entire breast. However, recent research has shown that in certain situations, it may be possible to preserve the breast.

The study will collect data on the safety of this treatment approach and its effects on patients. The treatment follows standard breast cancer care practices, involving 30 patients from Helsinki and Turku University Hospitals. Patients are carefully selected based on specific criteria, such as tumor size, localization, and prior treatment history. Special attention is given to the planning of radiation therapy and surgical techniques.

The goal is to develop new treatment strategies that allow breast preservation even in cases of recurrent breast cancer, providing patients with high-quality and individualized care.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • The patient has a diagnosed breast cancer or tumor area in the breast with a maximum diameter of 3 cm, where a previous breast-conserving surgery has been performed (either invasive breast cancer or carcinoma in situ, DCIS).

The patient has only a local recurrence, and imaging studies show no suspicion of metastases outside the breast (preoperative staging N0M0).

At least 3 years have passed since the completion of prior radiation therapy. The new breast cancer can be technically treated with another breast-conserving surgery using a technique that does not require tissue transfer from areas opposite the removed tumor to restore the shape of the breast.

The patient is at least 55 years old at the time of surgery. The patient is willing to participate in the study. The patient is capable of providing informed consent.

Exclusion Criteria
  • A booster dose, also known as a "boost," was administered during prior radiation therapy.

Preoperative assessments suggest multifocal breast cancer, with the tumor area to be removed exceeding 3 cm.

The planned radiation therapy per the study protocol cannot be administered due to factors such as shoulder joint stiffness, a pacemaker located in the radiation field, or a skin condition (e.g., scleroderma).

The patient is unable to provide informed consent or is unwilling to participate in the study.

Metastases outside the breast (e.g., axillary or distant metastases) are present.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
A treatment-limiting radiation therapy complication.From the beginning of the radiotherapy until 30 days after finishing the therapy

Any complication related to radiation therapy, that would limit completing the radiotherapy

Secondary Outcome Measures
NameTimeMethod
Quality of life5 years from surgery

Patients are asked to complete a quality of life questionnaire before the surgery and at 3 months, 1 year, 3 years, and 5 years after the surgery

Second Breast Cancer Recurrence5 years from surgery

The patients are surveilled for second breast cancer recurrence

Secondary malignancies5 years

The patients are surveilled for any other secondary malignancy than breast cancer

Trial Locations

Locations (2)

Helsinki University Hospital

🇫🇮

Helsinki, Finland

Turku University Hospital

🇫🇮

Turku, Finland

© Copyright 2025. All Rights Reserved by MedPath